| Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (NCT07459920) | National Cancer Institute, Naples | 2026-04-01 |
| Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy (NCT07213557) | National Cancer Institute, Naples | 2026-03-13 |
| Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 (NCT07290894) | National Cancer Institute, Naples | 2026-03-12 |
| REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) (NCT07302451) | National Cancer Institute, Naples | 2026-02-23 |
| Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Trial (NCT07314853) | National Cancer Institute, Naples | 2026-02-01 |
| Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. (NCT07267780) | National Cancer Institute, Naples | 2025-12-01 |
| STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer (NCT07213570) | National Cancer Institute, Naples | 2025-10-16 |
| Financial Toxicity in Patients With Early-stage Breast Cancer (NCT07354165) | National Cancer Institute, Naples | 2025-09-30 |
| Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer (NCT07269249) | National Cancer Institute, Naples | 2025-09-01 |
| Application of da Vinci SP for Endometrial Cancer Surgical Staging (NCT07027046) | National Cancer Institute, Naples | 2025-04-03 |
| ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer (NCT06714357) | National Cancer Institute, Naples | 2025-03-12 |
| Development of a Platform for the Clinical Implementation of Precision Oncology in the Central-Southern Regions of Italy (COESIT) (NCT06894823) | National Cancer Institute, Naples | 2024-12-10 |
| Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease (NCT06886282) | National Cancer Institute, Naples | 2024-11-05 |
| Multi-omic Approach to Cancer Diagnosis: the Italian Network of Excellence for Advanced Diagnosis (INNOVA) (NCT06884878) | National Cancer Institute, Naples | 2024-10-08 |
| Effectiveness of Nurse Tele-consultation on the Quality of Elective Colonoscopy, Procedure-related Anxiety, and Financial Toxicity (NCT06887244) | National Cancer Institute, Naples | 2024-06-24 |
| Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (NCT06509126) | National Cancer Institute, Naples | 2024-06-12 |
| Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis (NCT06905145) | National Cancer Institute, Naples | 2024-05-03 |
| PRO for Fighting FT in Ovarian Cancer (NCT06032975) | National Cancer Institute, Naples | 2023-10-30 |
| Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas (NCT06236464) | National Cancer Institute, Naples | 2023-09-25 |
| The Study is Observational and Retrospective: Lifestyle, BMI and Activity Physical. (NCT06866093) | National Cancer Institute, Naples | 2023-09-04 |
| Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma (NCT06341764) | National Cancer Institute, Naples | 2023-09-01 |
| The ONCOCAMP Study (NCT06270602) | National Cancer Institute, Naples | 2023-07-14 |
| Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer (NCT06893861) | National Cancer Institute, Naples | 2023-07-06 |
| Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (NCT05821556) | National Cancer Institute, Naples | 2023-06-12 |
| Prediction of True Oligo-metastatic Disease. (NCT05806151) | National Cancer Institute, Naples | 2023-01-17 |
| Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt) (NCT06905262) | National Cancer Institute, Naples | 2023-01-02 |
| A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (NCT06218511) | National Cancer Institute, Naples | 2022-11-22 |
| Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. (NCT05817227) | National Cancer Institute, Naples | 2022-05-19 |
| MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (NCT05255471) | National Cancer Institute, Naples | 2022-01-21 |
| MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (NCT05233982) | National Cancer Institute, Naples | 2021-12-09 |
| PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) (NCT04854213) | National Cancer Institute, Naples | 2021-10-06 |
| Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE) (NCT04726228) | National Cancer Institute, Naples | 2021-06-21 |
| Molecular Data and Their Correlations With Clinical Outcomes in Gynecological Cancer Patients. (NCT05733793) | National Cancer Institute, Naples | 2021-06-16 |
| A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (NCT04893785) | National Cancer Institute, Naples | 2021-06-15 |
| Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) (NCT04893356) | National Cancer Institute, Naples | 2021-01-20 |
| "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. (NCT05818865) | National Cancer Institute, Naples | 2021-01-18 |
| MAnagement of METastatic Disease in Campania (MAMETIC) (NCT04595032) | National Cancer Institute, Naples | 2020-09-11 |
| Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer (NCT04397601) | National Cancer Institute, Naples | 2020-05-11 |
| Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (NCT04317092) | National Cancer Institute, Naples | 2020-03-19 |
| Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies (NCT05818020) | National Cancer Institute, Naples | 2020-03-02 |
| Study on Gynecological Rare Cancers (NCT05733806) | National Cancer Institute, Naples | 2019-10-14 |
| Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (NCT03874026) | National Cancer Institute, Naples | 2019-09-05 |
| Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide. (NCT04139772) | National Cancer Institute, Naples | 2019-09-01 |
| Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (NCT04091204) | National Cancer Institute, Naples | 2019-07-04 |
| Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (NCT04310176) | National Cancer Institute, Naples | 2019-05-24 |
| Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma (NCT04129281) | National Cancer Institute, Naples | 2019-01-23 |
| A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (NCT03975114) | National Cancer Institute, Naples | 2018-12-20 |
| Validation of the Italian Version of the PRO-CTCAE (NCT04416672) | National Cancer Institute, Naples | 2018-07-01 |
| Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study (NCT04123925) | National Cancer Institute, Naples | 2018-06-12 |
| Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (NCT04425239) | National Cancer Institute, Naples | 2018-05-21 |
| Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer (NCT03503786) | National Cancer Institute, Naples | 2018-04-01 |
| Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT03410784) | National Cancer Institute, Naples | 2018-04-01 |
| Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy (NCT03473379) | National Cancer Institute, Naples | 2018-03-01 |
| REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis (NCT03380858) | National Cancer Institute, Naples | 2017-11-02 |
| IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients (NCT03203005) | National Cancer Institute, Naples | 2017-09-18 |